Medprin Regenerative Medical Technologies Co. Ltd. Cash Flow-to-Debt Ratio
Medprin Regenerative Medical Technologies Co. Ltd. cash flow-to-debt ratio. Medprin Regenerative Medical Technologies Co. Ltd. (301033) has a Cash Flow-to-Debt Ratio of 1.17x as of December 2024, meaning its operating cash flow of CN¥116.38 Million could theoretically repay 1% of its total liabilities (CN¥99.57 Million) in one year. Check 301033 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Medprin Regenerative Medical Technologies Co. Ltd. (2019–2024)
Cash flow-to-debt ratio of Medprin Regenerative Medical Technologies Co. Ltd. from 2019 to 2024. Historical debt coverage capacity for Medprin Regenerative Medical Technologies Co. Ltd. across 6 annual periods. Check Medprin Regenerative Medical Technologie cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Medprin Regenerative Medical Technologies Co. Ltd. Cash Flow-to-Debt Ratio by Year (2019–2024)
Medprin Regenerative Medical Technologies Co. Ltd. cash flow-to-debt ratio by year from 2019 to 2024. Year-by-year debt coverage analysis for Medprin Regenerative Medical Technologies Co. Ltd.. For the full cash flow conversion analysis, see 301033 operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 1.17x | CN¥116.38 Million | CN¥99.57 Million | ▲ +64.0% |
| 2023 | 0.71x | CN¥107.69 Million | CN¥151.11 Million | ▲ +110.0% |
| 2022 | 0.34x | CN¥48.31 Million | CN¥142.34 Million | ▼ -12.8% |
| 2021 | 0.39x | CN¥66.51 Million | CN¥170.92 Million | ▲ +34.6% |
| 2020 | 0.29x | CN¥33.91 Million | CN¥117.26 Million | ▼ -65.5% |
| 2019 | 0.84x | CN¥31.27 Million | CN¥37.27 Million | — |